美银将诺和诺德目标价从375丹麦克朗下调至315丹麦克朗。 ...

The Novo Nordisk headquarters in Bagsvaerd, Denmark. Metsera Inc. shares tumbled after Novo Nordisk A/S declined to further raise its offer for the US maker of an experimental weight-loss drug, bringing a bidding war with Pfizer Inc. to an end. Most Read from Bloomberg The shares slumped as much as 16% to $70.12 in US premarket trading. The stock more than quadrupled from its January initial public offering through Friday’s close. Novo, the maker of Wegovy and Ozempic, decided to drop out of the running ...

Group 1 - Novo Nordisk (NVO.US) has decided not to submit a new acquisition bid for Metsera (MTSR.US), which has been acquired by Pfizer (PFE.US) for approximately $10 billion [1] - Pfizer's acquisition of Metsera serves as a strategic entry point into the weight loss drug market, with a revised agreement offering a maximum price of $86.25 per share, representing a 159% premium over Metsera's closing price prior to Pfizer's initial announcement [1][2] - The acquisition proposal from Novo Nordisk raised "unacceptable legal and regulatory risks" for Metsera and its shareholders, while Pfizer's proposal has received approval from the Federal Trade Commission (FTC), ensuring transaction certainty [2] Group 2 - Metsera is developing a monthly-administered weight loss drug, which is expected to compete in the market alongside Novo Nordisk and Eli Lilly's weekly-administered weight loss drugs [2]

Group 1 - U.S. stock futures are higher, with Nasdaq futures gaining approximately 1.5% on Monday [1] - Monday.Com Ltd is expected to report quarterly earnings of 88 cents per share, an increase from 85 cents per share in the previous year [2] - The consensus estimate for monday.com's quarterly revenue is $312.26 million, up from $251 million a year earlier [2] Group 2 - Monday.Com shares fell 2.6% to $184.70 in pre-market trading [2] - Metsera Inc shares dipped 15% to $70.68 after Pfizer secured a $10 billion deal to acquire the company [4] - Ionis Pharmaceuticals Inc declined 11.5% to $65.00 following the disclosure of pivotal Phase 3 study results [4] - Other companies such as UniQure NV, Oscar Health Inc, Centene Corp, and Immunovant Inc also experienced declines in pre-market trading [4]

Group 1 - Major stock index futures are up, with Dow futures rising by 0.44%, S&P 500 futures increasing by 1.00%, and Nasdaq futures gaining 1.56% [1] - Prominent tech stocks are experiencing pre-market gains, with Nvidia and AMD up over 3%, Oracle and TSMC rising more than 2.5%, and Intel increasing nearly 2% [1] - Notable Chinese concept stocks are also up in pre-market trading, with Xpeng Motors rising over 5.5%, Li Auto and NIO increasing nearly 2%, and NetEase and Pinduoduo gaining over 1.5% and 1.3% respectively [1] Group 2 - WeRide has received the first city-level Robotaxi operating license outside the U.S., allowing for fully autonomous operations in Abu Dhabi, marking a significant milestone in the Middle East [1] - Pfizer has successfully acquired Metsera for $10 billion, a biotech company developing a monthly-administered weight loss drug, positioning itself competitively against Novo Nordisk and Eli Lilly's weekly-administered products [1][2] - Rumble is set to acquire German AI company Northern Data, which will expand Rumble's cloud business and accelerate its international growth strategy [2] - Robinhood plans to launch a new fund allowing retail investors to invest in private AI companies, managed by its subsidiary Robinhood Ventures, focusing on a concentrated portfolio of top private firms [2] - UBS strategists predict the S&P 500 index will reach 7500 points by 2026, representing an 11% increase, driven by approximately 14% earnings growth, with nearly half coming from tech companies [2]

Norway’s sovereign wealth fund is among investors renouncing a revamp of the board of directors at obesity-drug maker Novo https://t.co/SRLnVcRPn4 ...

Core Viewpoint - The recent pricing agreement for obesity drugs in the U.S. is milder than market expectations, particularly in the oral medication sector, which is expected to enhance industry growth potential through increased drug accessibility and patient adherence despite initial pricing pressures [1][2]. Group 1: Pricing Agreement Details - The U.S. government reached a pricing agreement with Eli Lilly (LLY.US) and Novo Nordisk (NVO.US) for obesity prescription drugs, effective November 6, 2025 [1]. - Monthly costs for Wegovy and Ozempic will be reduced to $350, Zepbound and the pending Orforgilpron will be priced at $346, and the starting dose for the future oral Wegovy will be $150 [1]. - Key breakthroughs include: 1. Opening pathways for Medicare to reimburse obesity medications, which were previously not covered [1]. 2. Setting a drug price of $245 at the Medicare level, with patients only responsible for $50 [1]. 3. Allowing state Medicaid programs to negotiate for similar low prices with pharmaceutical companies [1]. Group 2: Impact on Patient Adherence and Company Revenue - The pricing reduction is expected to significantly lower patient medication costs, potentially covering about 80% of Medicare beneficiaries, including those with type 2 diabetes and obesity-related complications [1]. - Initial price drops may impact pharmaceutical revenues, with Novo Nordisk anticipating a 2%-4% revenue hit in 2025, equating to a net price decline of 10%-15% [2]. - Approximately 70% of patients currently discontinue treatment within 12 months, but lower out-of-pocket costs are expected to improve adherence, particularly for those relying on compounded medications [2]. Group 3: Company Ratings and Future Outlook - Eli Lilly plans to offer a low out-of-pocket option for the oral formulation Orforglipron starting April 2026, with the drug currently under FDA fast-track review and expected to launch in Q1 2026 [2]. - HSBC maintains a "Hold" rating on Eli Lilly with a target price of $850, citing that while the product pipeline and long-term growth potential are strong, the current stock price reflects optimistic expectations, leading to short-term valuation pressures [2]. - For Novo Nordisk, despite risks of stock price declines due to pricing changes, improvements in Medicare access and advancements in key clinical trials like EVOKE may help the company regain market leadership and create conditions for a strong stock rebound, leading to a "Buy" rating with a target price of 445 Danish Krone [2].

Group 1: US Government Shutdown and Market Reactions - The Senate has advanced a bill to end the US government shutdown and fund federal agencies through January, with a potential vote in the House soon [2][8] - Global equities are gaining on signs that the deadlock may be ending, with US and European futures pointing higher [2] - The market has shown resilience, rallying despite concerns over the shutdown, indicating that other factors, such as AI valuation concerns, are more influential on market movements [5][6][22] Group 2: NASDAQ and Corporate Developments - The NASDAQ is looking to rebound after its worst week since April, with a notable rally off its lows on Friday [3][10] - Novo Nordisk lost a bidding war for Metsera, with Pfizer closing a $10 billion deal for the US biotech company, prompting Novo Nordisk to explore other acquisition options [3] - The market is differentiating between companies based on their AI capital expenditure, with significant volatility observed in tech stocks [20][24] Group 3: Economic Indicators and Consumer Confidence - Recent consumer confidence data has been disappointing, suggesting a potential weakening of the US consumer, which could impact economic growth [36][38] - The ongoing government shutdown has raised concerns about its impact on travel and economic activity, particularly during the Thanksgiving season [7][18] - Despite challenges, the labor market remains relatively stable, with low unemployment rates and ongoing capital expenditure driving economic growth [38][40] Group 4: Financial Sector Insights - The financial sector has seen a rerating, with European banks achieving significant earnings revisions and trading above one times price to book for the first time in 15 years [44] - There are expectations of deregulation and asset price inflation supporting investment banking activities, which could benefit banks in both the US and Europe [45] - The tech sector is experiencing strong earnings growth, with financials also showing robust performance, indicating a broader trend of recovery in these sectors [43][47]

Core Viewpoint - Norway's sovereign wealth fund, the largest in the world, will abstain from voting on new board members, including the chair, at Novo Nordisk's extraordinary shareholders' meeting scheduled for November 14 [1] Group 1 - The decision to abstain from voting indicates a significant stance by Norway's sovereign wealth fund regarding corporate governance at Novo Nordisk [1] - The extraordinary shareholders' meeting is set for November 14, highlighting an upcoming critical event for Novo Nordisk [1]

Core Insights - Novo Nordisk has entered into a partnership with Emcure Pharmaceuticals to exclusively distribute and market the weight-loss drug Poviztra semaglutide injection in India [1] Company Summary - Novo Nordisk is expanding its market presence in India through a strategic partnership with Emcure Pharmaceuticals [1] - Emcure Pharmaceuticals will handle the distribution and marketing of Poviztra semaglutide injection, indicating a focus on the growing demand for weight-loss solutions in the Indian market [1] Industry Summary - The collaboration highlights the increasing interest in weight-loss medications within the pharmaceutical industry, particularly in emerging markets like India [1] - The partnership may signal a trend towards more localized distribution strategies for global pharmaceutical companies aiming to penetrate specific regional markets [1]